natgillin/translations-raw huggingface dataset:
a nucleic acid sequence coding for a plant pentose transporter, wherein the plant pentose transporter preferably originates from Arabidopsis, preferably Arabidopsis thaliana, and comprises an amino acid sequence, which is at least 70%, preferably at least 80%, more preferably at least 90% identical to the amino acid sequence of SEQ ID NO: 1 and has an in vitro and/or in vivo pentose transport function, or functional equivalents of SEQ ID NO: I having an in vitro and/or in vivo pentose transport function, 
(a)nukleinskokiselinski slijed koji kodira biljni transporter pentoza, gdje biljni transporter pentoza ima aminokiselinski slijed koji je najmanje 70%, po mogućnosti najmanje 80%, poželjnije najmanje 90% istovjetan aminokiselinskom slijedu SEQ ID NO: 1, te in vitro iili in vivo ima funkciju transporta pentoza, (b)
The treatment typically comprises the eradication of Helicobacter pylori in the subject. In some embodiments, the method of treatment comprises administering to said patient a therapeutically effective amount of a composition comprising (1) an immediate release first dosage composition comprising of at least two antibiotics; (2) a delayed release second dosage composition comprising a proton pump inhibitor and a coating; and (3) an outer layer encapsulating the first dosage and the second dosage compositions. 
(1) pripravak prve doze s trenutnim otpuštanjem u obliku komprimiranih minitableta, pripravak prve doze s trenutnim otpuštanjem koji se sastoji od najmanje dva antibiotika te (2) pripravak druge doze s odgođenim otpuštanjem u obliku komprimiranih minitableta, pripravak druge doze s odgođenim otpuštanjem koji se sastoji od inhibitora protonske pumpe i obloge, naznačen time što je, kada se testira u uređaju s košaricom, obloga pripravka druge doze s odgođenim otpuštanjem osmišljena tako da ispunjava kriterije profila otapanja u dvofaznom testu u uređaju s košaricom:
The delivery system of claim 1, wherein the closed mechanical system is an article of machinery or equipment. 
Sustav za dovođenje prema zahtjevu 1, naznačen time da zatvoreni mehanički sustav je motor s unutarnjim izgaranjem.
The isolated antibody or protein of claim 9, which is produced by recombinant expression in a cell line with deficient expression of the FUT8 gene encoding fucosyltransferase, thereby increasing ADCC activity of antibodies produced therein as compared with a cell line expressing the wild type FUT8 gene. 
Postupak prema zahtjevu 31, naznačen time, da navedena stanična linija je stanica sisavca nedovoljna za ekspresiju gena koji kodira fukoziltransferazu, poželjno je to CHO stanična linija bez gena FUT8.
the amino acid in the position corresponding to position F10 in SEQ ID NO: 10 is L, and the amino acid in the position corresponding to position K55 in the lambda light chain of SEQ ID NO: 10 is N. 
Konstrukt nukleinske kiseline, naznačen time, da kodira varijabilno područje teškog lanca (VH) od SEQ ID br. 6 i varijabilno područje lakog lanca (VL) od SEQ ID br. 10.
Compound 1 for use in the preparation of a pharmaceutical composition for the treatment or prevention of diabetes. 
3. = Spoj prema patentnom zahtjevu 1, za uporabu kao lijek za liječenje dijabetesa.
A process for the preparation of the composition according to claim 8, comprising the step of: 
Postupak za pripravu pripravak u skladu s patentnim zahtjevom 8, naznačen time, da se sastoji iz sljedećeg koraka: a.
System for the directional horizontal drilling in the ground of a shank and for subsequently bringing a conveyor pipeline into the shank, comprising: 
Sustav za usmjereno vodoravno bušenje provrta (10) u zemlji i zatim za uvođenje transportnog cjevovoda (6) u provrt (10), obuhvaća:
If a separate container is used, this can be sent by post after it has been closed. 
Ako se koristi odvojeni spremnik, ovaj može biti poslan poštom nakon što se zatvori.
A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je glioblastom.
The apparatus according to claim 9, wherein during a third predetermined period of operation, the second piston part abuts the piston seat cover and moves the piston seat cover toward the first piston part, thereby compressing the piston seat spring and reducing the piston seat cavity volume. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time da tijekom trećeg prethodno određenog perioda rada, drugi dio klipa se naslanja na poklopac sjedišta klipa (130) i pomiče poklopac sjedišta klipa (130) prema prvom dijelu klipa, te tako stlačuje oprugu sjedišta klipa (150) i smanjuje volumen šupljine sjedišta klipa.
It could be operated to apply a substance on crop, whether growing in the field or cut and laying in the field, as the vehicle drives by or over it. 
Može raditi na nanošenju neke supstance na usjev, bilo da još raste u polju ili da je porezan i leži u polju dok se vozilo kreće uz ili preko njega.
A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 27 and a pharmaceutically acceptable carrier or excipient. 
Oprema koja sadrži spremnik koji sadrži učinkovitu količinu spoja ili farmaceutski prihvatljive soli spoja prema zahtjevu 1 ili zahtjevu 20.
The system as claimed in claim 1 wherein the first electrode has an axially aligned stem having a forward portion having diverging and converging conical portions for self-sealing against an inner insulating sleeve and wherein the electrode has a bulbous tip. 
Sustav prema zahtjevu 1, pri čemu prva elektroda (2b.1) ima aksijalno centriran štap s prednjim dijelom sa stožastim dijelovima koji se šire i sužavaju te se mogu sami zatvoriti prema unutarnjem rukavu za izolaciju i pri čemu prva elektroda (2b.1) ima ispupčen vrh.
A modified serpin according to any one of clauses 94 to 98, 101 or 102 comprising an amino acid sequence having at least 70% sequence identity to residues 25-418 of SEQ ID NO: 12, wherein the P4 residue in the RCL of the modified serpin is A, the P2 residue is K, P1 residue is R and the P1' residue is K. 
Modificirani serpin prema bilo kojem od zahtjeva 1 do 11, naznačen time, da on obuhvaća aminokiselinsku sekvencu koja ima najmanje 70% identiteta sekvence prema ostatcima 25-418 od SEQ ID NO: 12, pri čemu ostatak P4 u RCL-petlji od modificiranog serpina je A, ostatak P2 je K, ostatak P1 je R i ostatak P1' je Ki.
A safety glove (2) comprising at least one protective element or attachment (1) according to claim 1, the element or attachment (1) being glued or fixed to the top dorsal part of at least one of the fingers of said glove. 
Zaštitna rukavica (2), naznačena time što sadrži najmanje jedan zaštitni element ili dodatak (1) u skladu s patentnim zahtjevom 1, gdje element ili dodatak (1) je zalijepljen ili pričvršćen na gornji dorzalni dio najmanje jednog od prstiju navedene rukavice.
and wherein n is an integer from 0 to 6. 
i gdje je n cijeli broj od 0 do 6.
reacting an intermediate of formula (II) with an appropriate reagent in a reaction-inert solvent with the formation of a compound of formula (I). 
reakciju intermedijera formule (II) sa odgovarajućim reagensom u reakcijski-inertnom otapalu uz dobivanje spoja formule (I) [image]
A system according to claim 12, wherein the evaporator temperature of the refrigeration system is -15°C (5°F) or below. 
Sustav prema zahtjevu 12, naznačen time da je temperatura isparivača u rashladnom sustavu -15°C (5°F) ili niža.
The isolated antigen binding protein of item 1 comprising either: a light chain variable domain sequence selected from the group consisting of; 
2. -Anti-TSLP ljudsko protutijelo iz patentnog zahtjeva 1, sadrži: a. varijabilnu domenu lakog lanca izabranu iz grupe koja sadrži: i.
The process according to claim 1, wherein the solvent is used in an amount of from 50 to 1000 g in relation to 100 g of 2-amino-3-chloro-5-trifluoromethylpyridine. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se koristi otapalo u količini od 50 do 1000 g u odnosu na 100 g 2-amino-3-kloro-5 trifluorometilpiridina.
The drug-delivery device of claim 2, wherein the body further comprises a canalicular extension attached to the distal tip portion of the body, wherein the canalicular extension is configured for insertion through the punctal aperture and the punctum and positioning in the lacrimal canaliculus. 
Naprava za unos lijeka u skladu s patentnim zahtjevom 2, naznačena time što tijelo dodatno sadrži produžetak za kanalić, spojen na distalni vršni dio tijela, gdje je produžetak za kanalić tako oblikovan da se može umetnuti kroz punktalni otvor i punktum, te staviti u suzni kanalić.
The soft chewable veterinary composition of any preceding claim wherein the surfactant is selected from polyoxyl 8 stearate (PEG 400 monostearate), polyoxyl 40 stearate (PEG 1750 monostearate), polyethylene glycol 12-hydroxystearate and polyethylene glycol 15 12-hydroxystearate. 
Mekani veterinarski pripravak za žvakanje u skladu s bilo kojim od prethodnih zahtjeva, naznačen time, da je tenzid odabran od polioksil-8-stearata (PEG 400 monostearata), polioksil-40-stearata (PEG 1750 monostearata), polietilenglikol-12-hidroksistearata i polietilenglikol-15-12-hidroksistearata.
The anti-Factor D antibody or antigen-binding fragment thereof of claim 1, wherein the light chain variable domain comprises: CDR-L1 having the amino acid sequence of SEQ ID NO: 16; CDR-L2 having the amino acid sequence of SEQ ID NO: 21; and CDR-L3 having the amino acid sequence of SEQ ID NO: 19, and the heavy chain variable domain comprises CDR-H1 having the amino acid sequence of SEQ ID NO: 23; CDR-H2 having the amino acid sequence of SEQ ID NO: 14; and CDR-H3 having the amino acid sequence of SEQ ID NO: 20. 
varijabilnu domenu lakog lanca, koja sadrži aminokiselinski slijed SEQ ID NO:7, gdje je CDR1 definiran sa SEQ ID NO:16, CDR2 je definiran sa SEQ ID NO:17, a CDR3 je definiran sa SEQ ID NO:19; i varijabilnu domenu teškog lanca, koja sadrži aminokiselinski slijed SEQ ID NO:8, gdje je CDR1 definiran sa SEQ ID NO:13, CDR2 je definiran sa SEQ ID NO:14, a CDR3 je definiran sa SEQ ID NO:20;
The monoclonal antibody or antigen-binding fragment thereof according to claim 1, wherein the reference antibody comprises a heavy chain and a light chain defined by one of the following pairs of sequences: 
Monoklonsko protutijelo ili njegov antigen-vezujući fragment prema patentnom zahtjevu 1, naznačeno time što referentno protutijelo sadrži teški lanac i lagani lanac definiran jednim od sljedećih parova sekvenci:
at least one vinyl copolymer block containing epoxy groups so that there is from 2.8% to 19% by weight of oxirane oxygen calculated on the total of the at least one block copolymer; 
barem vinilni kopolimerni blok koji sadrži epoksi skupine tako da ima od 0,7% do 19% težine oksiran kisika računato prema ukupnom bloku kopolimera; i
A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as claimed in claim 1 . 
Farmaceutski pripravak naznačen time da sadrži farmaceutski prihvatljiv nosač, te kao aktivni sastojak, terapeutski učinkovitu količinu spoja kako je zatraženo u bilo kojem od zahtjeva 1 do 18.
The method according to claim 1, wherein the Parkinson's disease is an early-stage Parkinson's disease. 
Farmaceutski pripravak za uporabu prema zahtjevu 5, naznačen time da Parkinsonova bolest je Parkinsonova bolest u ranoj fazi.
In accordance with claim 1, the present invention provides a method for producing acrylic acid, the method comprising the steps of: forming polypropiolactone at a first location comprising contacting beta-propiolactone with a polymerization catalyst comprising an acrylate anion; isolating at least some of the polypropiolactone; and pyrolyzing at least some of the isolated polypropiolactone to liberate acrylic acid at a second location. 
HR P20190420 T1 PATENTNI ZAHTJEVI Postupak proizvodnje akrilne kiseline, naznačen time što se postupak sastoji u koracima: dobivanja polipropiolaktona na prvoj lokaciji, koje se sastoju u stavljanju u kontakt B-propiolaktona s katalizatorom polimerizacije koji sadrži akrilatni anion; izdvajanja u najmanju ruku dijela polipropiolaktona; i piroliziranja u najmanju ruku dijela izdvojenog polipropiolaktona kako bi se oslobodilo akrilnu kiselinu na drugoj lokaciji.
Desirably, the channel activator is capable of activation of a channel in a gastroesophogeal neuron when administered to a subject 
(c) gingerola, i pri čemu navedeni pripravak sadrži aktivator kanala TRPVI1 pri čemu navedeni aktivator TRPVI1 kanala je kapsaicin ili drugi kapsaicinoid.
The method of claim 3 wherein said compound of Formula II is administered in the form of a transdermal patch, ointment, lotion, cream, or gel. 
Spoj za uporabu prema zahtjevu 6, naznačen time da je navedeni spoj za davanje u obliku transdermalnog flastera, masti, losiona, kreme ili gela.
water in an amount of about 2% to about 10% by weight of the composition and a carrier medium comprising 
vodu u količini od oko 2 masena % do oko 15 masenih % od sastava;
aryl is a homocycle selected from phenyl, naphthyl, acenaphthyl or tetrahydronaphthyl, each being optionally substituted with 1, 2 or 3 substituents, each substituent being independently selected from hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl C2-6alkenyl optionally substituted with phenyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl or mono- or dialkylaminocarbonyl; 
je homocikal odabran između fenil, nalftil, acenaftil ili tetrahidronaftil, svaki po izboru je supstituiran sa 1, 2 ili 3 supstituenta, svaki supstituent nezavisno je odabran između hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkil, Cogalkenil po izboru je supstituiran sa fenilom, haloalkilom, alkiloksi, haloalkiloksi, karboksilom, alkiloksikarbonilom, aminokarbonilom, morfolinilom ili mono- ili dialkilaminokarbonilom; aril!
The method according to claim 1, wherein the raw meal mixture is ground to finenesses (according to Blaine) of 1500 to 10000 cm2/g. 
Postupak sukladno barem jednom od zahtjeva 1 do 6, naznačen time što je sirova smjesa za hranu samljevena na finoću od 1500 do 10000 cm'/g, poželjno od 2000 do 4000 cm?/g.
The process according to claim 1, wherein the water to be purified contains at least one compound selected from polycyclic compounds, cholesterol, and/or endocrine disrupting compounds. 
Postupak prema zahtjevu 17, pri čemu voda koju treba pročistiti sadrži nečistoće teških metala, organske nečistoće, mikroorganizme, i/ili barem jedan spoj izabran od policikličnih spojeva, kolesterola, i/ili spojeva koji izazivaju endokrine poremećaje.
It is further disclosed that at least a portion of the water insoluble contaminants may be separated from the ligno-cellulosic biomass in the extraction vessel. 
Proces iz bilo kojeg od patentnih zahtjeva 1 do 10, gdje je barem dio u vodi netopljivih onečišćenja odvojen iz ligno-celulozne biomase u posudi za ekstrakciju.
The layers were separated and the organic phase evaporated to dryness. 
Slojeve se razdvoji, a organsku fazu otpari do suhog.
The residue is purified by column chromatography (silica gel 230-400 mesh, mobile phase methanol:ethyl acetate 30:70) to get 3-(4-octylbenzylamino)cyclopentane-1,1-dicarboxylic acid ethyl ester as a white solid. 
Ostatak se pročisti kromatografijom na stupcu (silikagel veličine čestica 0,066-0,037 mm (230-400 mesh), pokretna faza metanol/etil-acetat 30:70) kako bi se dobilo etilni ester 3-(4-oktilbenzilamino)ciklopentan-1,1- dikarboksilne kiseline u obliku bijele krutine.
Number of mice showing respiratory distressa 
Broj međunarodne objave:
processing the solid formulation to produce a uniform powder, said uniform powder including at least a portion of the powder in a phase characterized by an XRPD mesopeak. 
obrade čvrste formulacije kako bi se dobilo jednolični prah, gdje navedeni jednolični prah sadrži u najmanju ruku dio praha u fazi naznačenoj time što ima XRPD međusignal.
Donepezil hydrochloride hydrate in the composition according to the invention remains unchanged. 
Donepezil hidroklorid hidrat u pripravku prema izumu ostaje nepromijenjen.
an extractor configured to extract the constellation values corresponding to Layer 1 signaling data from the frequency-deinterleaved constellation values corresponding to Layer 1 signaling data and Layer 1 header; 
dio za izlučivanje (r1917-L1, r1912-L1) konfiguriran za izlučivanje konstelacijskih vrijednosti koje odgovaraju signalnom podatku L1 iz konstelacijskih vrijednosti raspletenog vremena koje odgovaraju signalnom podatku L1 i zaglavlju razine 1;
The 5a-androstane-3B,5,6B-triol for use according to claim 1, wherein the neuron damage is caused by spinal cord ischemia. 
a-androstan-3B,5,6B-triol za uporabu u skladu s patentnim zahtjevom 1, pri čemu je oštećenje neurona uzrokovano ishemijom leđne moždine.
Freight container according to any one of the preceding claims, wherein at least the outer length of the freight container corresponds with the sizes and dimensions of a standard freight container, especially a 45 foot container, or wherein the freight container is formed as a 45 foot container, preferably as a so-called 45 ft. pallet wide container, or wherein the cargo floor (3) is at least 2.4 meter wide and at least 13.2 meter long, such as to accommodate at least 33 Euro-pallets. 
Teretni kontejner sukladno bilo kojem od prethodnih zahtjeva, čemu barem vanjska dužina teretnog kontejnera odgovara veličinama 1 dimenzijama standardnog teretnog kontejnera, osobito kontejnera od 45 stopa, ili pri čemu je teretni kontejner oblikovan kao kontejner od 45 stopa, preporučljivo kao takozvani kontejner čije su palete 45 ft. široke, ili pri čemu je pod (3) tereta širok najmanje 2,4 metara i dugačak najmanje 13,2 metara, tako da prima najmanje 33 Euro palete.
means (2476a; 2476b) for bit de-interleaving the multiplexed bits; and means (253) for decoding Physical Layer Pipe, PLP, data of the bit-deinterleaved bits according to the FEC method. 
rasplitač bitova (2476a; 2476b) za rasplitanje multipleksiranih bitova; i dekoder za ispravak pogrešaka (253) za dekodiranje za ispravak pogrešaka bitova za rasplitanje.
A process for the preparation of a compound of formula (I) wherein Hal represents fluoro or chloro and R1 and R2 represent, independently from one another, hydrogen or one of the meanings of Hal; in which process a compound of formula (II) is converted to a corresponding alkyl, fluoroalkyl or aryl sulfonic acid ester, which is then reacted with an alkali metal nitrite in the presence of a suitable crown ether in a polar non-nucleophilic solvent at a temperature of -10 to 50°C to give the compound of formula (I). 
i R", međusobno neovisno, predstavljaju vodik ili jedno od značenja Hal; naznačen time što u navedenom postupku spoj formule (II) se prevodi u odgovarajući ester alkil-, fluoralkil- ili arilsulfonske kiseline, koji zatim reagira s nitritom alkalnog metala, u prisutnosti pogodnog krunastog etera, u polarnom nenukleofilnom otapalu, na temperaturi od -10 *C do 50 "€, kako bi se dobilo spoj formule (D).
For liquids, conventional spray techniques are less than effective at these low rates. 
Za tekućine je konvencionalna tehnika raspršivanja manje nego učinkovita kod ovako malih odnosa.
A chamber (12) as claimed in any preceding claim, wherein the roof (42) comprises a framework of steel beams (44) supporting an impervious covering of sheet material (48). 
Komora (12) prema bilo kojem od prethodnih zahtjeva, naznačena time, da se krov (42) sastoji od okvira od čeličnih greda (44) koji pridržava nepropusni pokrov od lima (48).
In a further aspect, the invention relates to a T cell receptor which binds to a peptide of the invention, optionally in a complex with an MHC molecule, and preferably is reactive with said peptide, or a polypeptide chain of said T cell receptor. 
T stanični receptor koji se specifično veže za peptid sukladno patentnom zahtjevu 1 ili 2, izborno u kompleksu s MHC molekulom, naznačen time, što je T stanični receptor odabran iz skupine sastavljene od:
Aclidinium in free or pharmaceutically acceptable salt form for use in treating a respiratory condition selected from asthma and chronic obstructive pulmonary disease in a patient in need of such treatment, said use comprising (i) administering once daily an emitted dose of aclidinium equivalent to 360 µg (plus/minus 35%) aclidinium bromide, or (ii) administering twice daily an emitted dose of aclidinium equivalent to 360 µg (plus/minus 35%) aclidinium bromide. 
Aklidinij u slobodnom obliku ili u obliku farmaceutski prihvatljive soli za primjenu u liječenju kronične opstruktivne plućne bolesti u bolesnika kojem je potrebno takvo liječenje, pri čemu se spomenuta primjena sastoji od davanja inhalacijom jednom ili dvaput dnevno odmjerene nominalne doze aklidinija jednake 400 mikrograma (plus/minus 10 %) aklidinijevog bromida.
Uses of Up-Modulators of the Immune System 
Datum objave europske prijave patenta:
is C1-C4 linear alkyl or C3-C4 branched alkyl; or a pharmaceutically acceptable salt thereof. 
R* je Ci-Cu nerazgranati alkil ili C32-C, razgranati alkil; ili njegova farmaceutski prihvaljiva sol.
Cy is cyclopropyl or cyclobutyl, wherein the cyclopropyl or cyclobutyl is optionally substituted with one or two groups selected from alkyl and hydroxyl; 
je –NHCH2Cy; Cy je ciklopropil ili ciklobutil, pri čemu je ciklopropil ili ciklobutil opcionalno supstituiran s jednom ili dvije skupine odabrane između alkila i hidroksila;
In case the water to be purified contains one or more polycyclic compounds, cholesterol, and/or endocrine disrupting compounds, the surface-reacted natural calcium carbonate is preferably used in combination with activated carbon. 
Postupak prema zahtjevu 17, pri čemu voda koju treba pročistiti sadrži nečistoće teških metala, organske nečistoće, mikroorganizme, i/ili barem jedan spoj izabran od policikličnih spojeva, kolesterola, i/ili spojeva koji izazivaju endokrine poremećaje.
Architecture system of a local grid (10) according to claim 1, characterised in that said Logic F is of reduction and exclusion of the loads at the node n and includes at least the following Phases and Check phases, with particular correlations as also shown by the arrows in the relative diagram (Fig. 15) 
Arhitektura sustava lokalne mreže (10) prema zahtjevu 1, naznačena time da je navedena Logika F za smanjenje i isključivanje opterećenja na čvoru n i uključuje barem sljedeće Faze i Kontrolne faze sa specifičnim korelacijama kao što je prikazano strelicama u odgovarajućem dijagramu (slika 15) .
A pharmaceutical composition comprising a combination as defined in any one of claims 1 to 10 and one or more pharmaceutically acceptable excipients. 
Farmaceutski pripravak, naznačen time što sadrži polimorf, ili sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, kao i jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
One skilled in this art may further formulate the GnRH receptor antagonist in an appropriate manner, and in accordance with accepted practices, such as those disclosed in Remington's Pharmaceutical Sciences, Gennaro, Ed., Mack Publishing Co., Easton, Pa. 
Stručnjak također može formulirati antagonist receptora GnRH na odgovarajući način, te u skladu s prihvaćenom praksom, kao što je opisano u "Remington's Pharmaceutical Sciences", Gennaro, ur., Mack Publishing Co., Easton, PA, (1990.).
The system of claim 14, further comprising: a renewable energy generation system (436); and an energy storage system (460) coupled to the renewable energy generation system (436) to store energy generated by the renewable energy generation system. 
Sustav iz zahtjeva 14 kojeg nadalje čini: sustav proizvodnje obnovljive energije (436); 1 sustav skladištenja energije (460) sparen sustavu proizvodnje obnovljive energije (436) koji omogućuje skladištenje energije generirane sustavom proizvodnje obnovljive energije.